ECSP23002960A - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents

Fusiones heterodiméricas de relaxina y usos de las mismas

Info

Publication number
ECSP23002960A
ECSP23002960A ECSENADI20232960A ECDI202302960A ECSP23002960A EC SP23002960 A ECSP23002960 A EC SP23002960A EC SENADI20232960 A ECSENADI20232960 A EC SENADI20232960A EC DI202302960 A ECDI202302960 A EC DI202302960A EC SP23002960 A ECSP23002960 A EC SP23002960A
Authority
EC
Ecuador
Prior art keywords
relaxin
treatment
fusion polypeptides
heterodimer fusion
polypeptides
Prior art date
Application number
ECSENADI20232960A
Other languages
English (en)
Spanish (es)
Inventor
Judy Paterson
Isabelle Sermadiras
Esther Martin
Peng Ke
Monika Papworth
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of ECSP23002960A publication Critical patent/ECSP23002960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ECSENADI20232960A 2020-06-17 2023-01-16 Fusiones heterodiméricas de relaxina y usos de las mismas ECSP23002960A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17

Publications (1)

Publication Number Publication Date
ECSP23002960A true ECSP23002960A (es) 2023-03-31

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20232960A ECSP23002960A (es) 2020-06-17 2023-01-16 Fusiones heterodiméricas de relaxina y usos de las mismas

Country Status (17)

Country Link
US (3) US11795205B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168434A1 (cg-RX-API-DMAC7.html)
JP (2) JP7797423B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024994A (cg-RX-API-DMAC7.html)
CN (1) CN115916813B (cg-RX-API-DMAC7.html)
AR (1) AR125007A1 (cg-RX-API-DMAC7.html)
AU (3) AU2021290997C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025019A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186143A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003578A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000038A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230015A (cg-RX-API-DMAC7.html)
EC (1) ECSP23002960A (cg-RX-API-DMAC7.html)
IL (1) IL298786A (cg-RX-API-DMAC7.html)
MX (1) MX2022016340A (cg-RX-API-DMAC7.html)
TW (1) TWI899263B (cg-RX-API-DMAC7.html)
WO (1) WO2021255127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2025517100A (ja) 2022-05-07 2025-06-03 北京拓界生物医薬科技有限公司 リラキシン又は類似体の融合タンパク質及びその医薬的使用
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
IL321288A (en) 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
DK3107938T3 (da) * 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
US11161891B2 (en) * 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2026053559A (ja) 2026-03-25
EP4168434A1 (en) 2023-04-26
CN115916813A (zh) 2023-04-04
US20220017591A1 (en) 2022-01-20
JP2023530335A (ja) 2023-07-14
KR20230024994A (ko) 2023-02-21
CN115916813B (zh) 2026-03-24
CA3186143A1 (en) 2021-12-23
AU2024200074B2 (en) 2025-11-27
AU2025252658A1 (en) 2025-11-13
JP7797423B2 (ja) 2026-01-13
IL298786A (en) 2023-02-01
US20240025958A1 (en) 2024-01-25
AU2021290997A1 (en) 2023-02-09
US12187774B2 (en) 2025-01-07
AR125007A1 (es) 2023-05-31
MX2022016340A (es) 2023-01-24
CL2022003578A1 (es) 2023-06-09
US11795205B2 (en) 2023-10-24
US20250230214A1 (en) 2025-07-17
AU2021290997C1 (en) 2024-01-04
TWI899263B (zh) 2025-10-01
CR20230015A (es) 2023-02-17
CO2023000038A2 (es) 2023-01-16
BR112022025019A2 (pt) 2022-12-27
AU2024200074A1 (en) 2024-01-25
AU2021290997B2 (en) 2023-10-12
TW202214673A (zh) 2022-04-16
WO2021255127A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CL2022003578A1 (es) Fusiones heterodiméricas de relaxina y usos de las mismas
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
ECSP088262A (es) Proteínas de fusión de albúmina
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
PE20161324A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
CL2025000804A1 (es) Inserción de anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe.
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
CL2023003017A1 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
BR112023025331A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
CO2021007402A2 (es) Constructos de suministro para transcitosis y métodos relacionados
CO2021005083A2 (es) Distrofinas miniaturizadas y usos de las mismas
BR112018077225A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas
BR112022006923A2 (pt) Polipeptídeos recombinantes para localização celular regulável
CL2024003820A1 (es) Proteínas de fusión que comprenden un agonista mejorado del receptor glp-1 y sus usos
MX2021004185A (es) Polipeptidos analogos de la amilina humana y sus metodos de uso.
BR112023003526A2 (pt) Proteínas de fusão de coronavírus imunogênicos e métodos relacionados
PE20050197A1 (es) Anticuerpos de virus anti-dengue, composiciones, metodos y usos
AR123685A1 (es) Antagonistas del mrgx2
BR112017021016A2 (pt) preparação de proteína, composição farmacêutica, proteína de fusão, polinucleotídeo isolado, estrutura de ácido nucleico, método para tratamento de doença ou condição associada ao excesso de glutamato, e método de purificação de um polipeptídeo
BR112018076674A2 (pt) proteína de fusão entre o fator de viabilidade do cone derivado de bastonetes de forma curta e um peptídeo hidrofílico